I-Mab Announces Preliminary Proposal for Potential Dual Listing on the STAR Market of the Shanghai Stock Exchange
SHANGHAIand GAITHERSBURG, Md., July 27, 2021 /PRNewswire/ — I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that on July…
